Remove FDA Approval Remove Pharmacy Remove Regulation
article thumbnail

US FDA approves Pfizer’s migraine nasal spray Zavzpret

Pharmaceutical Technology

The company stated that the regulatory approval expands its migraine portfolio, which includes oral therapy for acute and preventive treatment. The regulator granted the approval based on two pivotal placebo-controlled, double-blind, randomised trials. The company expects to launch Zavzpret in pharmacies in July.

article thumbnail

Acute Leukemia Drug Revuforj Wins FDA Approval, Second Approval for Syndax this Year

XTalks

Syndax Pharmaceuticals’ Revuforj (revumenib) has won US Food and Drug Administration (FDA) approval for the treatment of relapsed or refractory (R/R) acute leukemia in patients aged one year and older who have a lysine methyltransferase 2A ( KMT2A, formerly MLL ) gene translocation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novo Nordisk weight-management drug lands FDA approval

Outsourcing Pharma

The pharmacy company's Wegovy (semaglutide) is the first therapy designated for chronic weight management that the agency has granted approval since 2014.

article thumbnail

Neurocrine Biosciences’ Crenessity Approved as First New Treatment in Decades for Rare Genetic Disorder CAH

XTalks

Currently, the standard treatment for CAH involves glucocorticoids, which replace cortisol and help regulate hormone levels. It also received the FDAs rare pediatric disease priority review voucher along with the approval, which will help expedite the agencys assessment of another application.

Genetics 116
article thumbnail

FDA accepts Outlook Therapeutics’ BLA for wet AMD treatment

Pharmaceutical Technology

On receiving approval, the treatment is expected to replace the requirement to use unapproved repackaged oncologic IV bevacizumab from compounding pharmacies for wet AMD treatment. The regulator has set 29 August 2023 as a Prescription Drug User Fee Act (PDUFA) goal date.

article thumbnail

Merck’s Winrevair Wins FDA Approval as First-in-Class Treatment for Pulmonary Arterial Hypertension (PAH)

XTalks

The US Food and Drug Administration (FDA) has given the nod to Winrevair (sotatercept-csrk injection, 45mg, 60mg) for the treatment of adults with pulmonary arterial hypertension (PAH) to increase exercise capacity, improve WHO (World Health Organization) functional class (FC) and reduce the risk of clinical worsening events.

article thumbnail

LegitScript Finds 1200 Percent Increase in Problematic Ads for Compounded GLP-1 Meds

XTalks

Compounded GLP-1 medications, created by specialized pharmacies under a special US Food and Drug Administration (FDA) allowance due to ongoing shortage, have become increasingly popular for weight loss. The report also shows a rapid rise in compounding pharmacies.

Pharmacy 104